RxDoctor Payments Data

Odette Evangelista, MD

Internal Medicine · Lewes, DENPI 1285969790

Payments from drug & device makers

$323in general payments, 2019–2025

Across 18 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$56
  • AstraZeneca$45
  • Lilly USA, LLC$35
  • GSK$26
  • Bristol Myers Squibb$24
  • Sunovion Pharmaceuticals Inc.$22
  • plus $116 from 7 others

What the payments were for

  • Food & beverage$323100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$323 in reported general payments places this provider in the 65th percentile of 477 internal medicine providers in Delaware.

See all internal medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$300,766
Medicare patients
709
Services billed
2,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$210,656
JardianceEmpagliflozin120$173,563
TrulicityDulaglutide41$88,346
EliquisApixaban63$84,212
MounjaroTirzepatide52$80,025
FarxigaDapagliflozin Propanediol33$50,056
Spiriva RespimatTiotropium Bromide24$26,338
JanuviaSitagliptin Phosphate12$19,338
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$18,610
Rosuvastatin Calcium891$15,958
XareltoRivaroxaban17$15,798
Breo ElliptaFluticasone/Vilanterol16$12,012
Atorvastatin Calcium688$8,457
SymbicortBudesonide/Formoterol Fumarate21$8,358
Losartan Potassium698$8,080

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$210,65699 claims
Boehringer IngelheimJardiance, Spiriva Respimat$56$199,901144 claims
Lilly USA, LLCTrulicity, Mounjaro$35$168,37293 claims
AstraZenecaFarxiga, Symbicort$45$58,41454 claims
GSKTrelegy Ellipta, Breo Ellipta$26$30,62235 claims
Johnson & JohnsonXarelto$15$15,79817 claims
AbbVieSynthroid$16$3,30797 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 477 internal medicine providers in Delaware.

Other internal medicine in Lewes

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →